Portugal INFARMED

Rybrevant (amivantamab) – Public funding assessment report available; approval granted

Original title: Rybrevant (amivantamab) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento

Portugal's INFARMED has approved public funding for Rybrevant (amivantamab); assessment report now available.

Low obligation Product class Pharmaceuticals Market Access & Reimbursement Portugal PharmaceuticalsReimbursement

Data : 14/08/2026

Dates and deadlines

Applies from

2026-08-14

Read the official source ↗

Published by Portugal INFARMED. HealthSignal links to the original document; the summary above is extracted from the source text.